AstraZeneca Tagrisso treats NSCLC patients with Phase 3 clinical trials with positive results

recently, AstraZeneca(http://announced that its heavyweight third-generation EGFR inhibitor Tagrisso (osimertinib, oxitinib) has achieved positive results in theof a critical phase 3 clinicaltrial
(http:// in the treatment of patients with primary or metastatic non-small cell lung cancer (NSCLC)About Tagrisso
Tagrisso is the firstdrug(http://that significantly improves total life span (OS) in these patients, and it also improves progressionless life (PFS) in patients with central nervous system metastatic tumorsAstraZeneca's heavy-duty anti-cancer drug Tagrisso is a third-generation, irreversible EGFR tyrosine kinase inhibitorTagrisso can inhibit EGFR activity that carries EGFR allergenic mutations and EGFR T790M resistance mutations, and also exhibit clinical activity in central nervous system metastatic tumorsTagrisso has been approved for listing in more than 70 countriesTagrisso has been approved in the United States, Japan and the European Union for first-line treatment for patients with advanced NSCLC who carry mutations in the EGFR gene2-line treatment of advanced NSCLC patients with EGFR T790M mutation has been approved in ChinaTagrisso's application for first-line treatment of patients with the EGFR gene mutation NSCLC has been accepted by the China Drug Administration and is expected to be approved in the second half of this yearabout FLAURA
in a randomized double-blind, multicenter Phase 3 clinical trial called FLAURA, nSCLC patients with mutations in the EGFR gene were treated with Tagrisso or erlotinib/gefitinibErlotinib and gefitinib were the standard treatments previously treated with these patientsPrevious trial results have shown that Tagrisso can significantly extend PFS (18.9 months vs10.2 months, p0.0001) compared to the active control group, but the OS data is not yet mature.